The dream of turning stem cell research into mainstream clinical therapies is making significant progress, as a large number of cell-based clinical studies are currently underway – some 2,700 stem cell clinical trials registered with www.clinicaltrials.gov between February 2000 and June 2010. While several companies have launched stem cell products onto the market, it’s the number of products in the pipeline that is starting to capture the attention of observers – including investors – who believe activity in current clinical trials is a telling sign of where the industry is headed.

Read this article:
Start-Ups Move Stem Cell Products Forward On Long Path To Market